Magnes AG
Zurich, Canton of Zurich, 8005, Switzerland
Location status: Recruiting
NCT Number: NCT07308418
The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. It is a low-risk pilot study meant to generate first evidence for future research.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Zurich, Canton of Zurich, 8005, Switzerland
Location status: Recruiting
Study Overview
This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life.
Rationale
Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals.
Participants
Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures.
Study Design and Procedures
Participants attend a single 45-minute session consisting of:
Informed consent and eligibility assessment
Instruction on NUSHU use
Two 2-minute walking tests (with and without vibration), in randomized order
A 15-minute washout between tests
Completion of the System-Usability-Scale (SUS) questionnaire
Continuous monitoring and documentation of safety events and perceived stability
The assessor is blinded regarding the stimulation condition to reduce bias.
Outcomes
Primary outcome:
Difference in self-selected gait speed between vibration vs. no-vibration conditions.
Secondary outcomes:
Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation.
Ethics & Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD.
Purpose:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NUSHU smart shoes give real time gait feedback during walking.
Time frame: Once during 120 seconds
Change in self-selected walking speed (m/s), measured over a 2-minute walking test with and without stimulation by the NUSHU. Walking speed is measured in m/s as a continuous metric variable, which is an objective and established way of measuring walking speed. The calculation is performed by dividing the total distance covered by the time in seconds (120 seconds).
Time frame: One visit of 45 minutes
Contact information is provided by the study sponsor or research team.
Magnes AG
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07734181
Basal Ganglia Diseases, Brain Diseases
Arlesheim, Basel-Landschaft, Switzerland
View Trial DetailsNCT07730073
Basal Ganglia Diseases, Brain Diseases
Kâğıthane, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07630545
Basal Ganglia Diseases, Brain Diseases
Adelaide, Australia
View Trial DetailsNCT07284784
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial Details